Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intellia Therapeutics (NTLA – Research Report), Integer Holdings (ITGR – Research Report) and ACADIA Pharmaceuticals (ACAD – Research Report).
Intellia Therapeutics (NTLA)
In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Intellia Therapeutics, with a price target of $70.00. The company’s shares closed last Thursday at $24.86.
According to TipRanks.com, Biliouris is a 1-star analyst with an average return of
Intellia Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $59.65, implying a 145.6% upside from current levels. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $60.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Integer Holdings (ITGR)
In a report released today, Robert Wasserman from Benchmark Co. maintained a Buy rating on Integer Holdings, with a price target of $130.00. The company’s shares closed last Thursday at $114.23.
According to TipRanks.com, Wasserman is a 1-star analyst with an average return of
Integer Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $125.29, representing a 10.2% upside. In a report issued on April 26, Bank of America Securities also reiterated a Buy rating on the stock with a $135.00 price target.
ACADIA Pharmaceuticals (ACAD)
Oppenheimer analyst Jay Olson maintained a Hold rating on ACADIA Pharmaceuticals today and set a price target of $17.00. The company’s shares closed last Thursday at $15.21, close to its 52-week low of $15.17.
According to TipRanks.com, Olson is a 5-star analyst with an average return of
ACADIA Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $28.56, a 63.2% upside from current levels. In a report issued on May 8, Mizuho Securities also maintained a Hold rating on the stock with a $21.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NTLA:
- Intellia Therapeutics reports Q1 EPS ($1.12), consensus ($1.38)
- Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
- Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
- Intellia Therapeutics to present updated data from Phase 1/2 study of NTLA-2002
- Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
